BRIEF-RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer

* RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.